An Observational, Retrospective, Real World Study of Osimertinib in Ethnic Chinese Patients With Locally Advanced/Metastatic T790M Mutation-Positive Non-small-cell Lung Cancer (NSCLC )Progressed on Previous Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI).
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 New trial record